PEAK6 Group’s Corcept Therapeutics CORT Stock Holding History

PEAK6 Group’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-800	Closed	-$11.9K	–	4468
2017 Q2	$9K	Buy	+800	New	+$8.7K	﹤0.01%	4383

Other funds holding CORT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PEAK6 Group's CORT Position: Q3 2017 in Review

PEAK6 Group sold out of Corcept Therapeutics (CORT) in Q3 2017, closing a stake of 800 shares — an estimated $11.9K sold.

PEAK6 Group first reported a position in CORT in Q2 2017 and held it in 1 quarter. The position peaked at $9K in Q2 2017. 189 funds tracked by Wall St. Rank hold CORT as of Q3 2017.

PEAK6 Group reported no remaining Corcept Therapeutics position as of Q3 2017 after selling out during the quarter.
PEAK6 Group sold 800 Corcept Therapeutics shares in Q3 2017, an estimated $11.9K.
PEAK6 Group first reported a position in Corcept Therapeutics in Q2 2017 and held it in 1 quarter.
PEAK6 Group's Corcept Therapeutics position peaked at $9K in Q2 2017.
189 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2017.

Based on PEAK6 Group's 13F filing for Q3 2017, filed 14 Nov 2017.